businessHosted by Bioevents Ltd
*One product. Multiple regulatory frameworks. Multiple owners. One patient.* ReCAP2027examines what happens when a medicinal product and a medical device become one therapeutic product, while the regulatory frameworks, quality systems, safety processes, and (internal) organisations behind them remain separate. Across two days, experts from industry, regulators and notified bodies will explore where combination products create gaps in responsibility, information and safety — and what can be done about them. *Learning Objectives* After ReCAP2027, participants will be better equipped to: See the whole product Understand how various global regulatory frameworks interact, and anticipate classification and borderline issues before they become development problems. Follow the risk across the lifecycle Understand how responsibility for benefit-risk decisions changes as a combination product moves from design and development through manufacturing and post-market surveillance. Connect the safety signals Recognise how drug-related, device-related, and use-related signals can become separated across different surveillance systems, and how to reconnect them. Close the organisational gaps Identify where internal silos, suppliers, responsibilities, and information flows can create blind spots in change control, complaint handling and risk management when dealing with combination devices. Leave with an action list Consolidate two days of insights into concrete first steps for your organization and a view on what must change at industry and regulatory level. *Who Should Attend?* ReCAP2027 is designed for experienced professionals working with drug-device combination products, including: - Regulatory affairs and regulatory policy professionals - Quality assurance and quality systems leaders - Pharmacovigilance, patient safety and device post-market surveillance specialists - Medical-device and combination-product engineers - Risk management and benefit-risk experts - Human factors and usability engineering specialists - Clinical development and medical affairs professionals - Post-market surveillance and product complaint teams - Supplier quality, alliance management and lifecycle management professionals - Pharmaceutical, biotechnology and medical-device manufacturers - Consultants working in these fields - Representatives from regulatory authorities and notified bodies
Date
Time
08:30 AMVenue
Brussels
Belgium
Hosted By
Bioevents Ltd
Brussels, Belgium | Sheraton Brussels Airport Hotel, Brussels Airport, 1930 Brussel, Belgium

All times are in Europe/Brussels.
See the combination product through the eyes of the patient, pharmaceutical and medical-device manufacturers, regulators and notified bodies. Discover where perspectives align, where they differ and why patient safety must remain the common goal.
Does today’s regulatory framework adequately support both product safety and patient safety? Explore the regulatory and quality challenges arising at the interface between medicinal products and medical devices, including important developments across global markets.
Combination products are moving rapidly beyond pre-filled syringes and drug-eluting stents. Discover the technologies, product concepts and regulatory questions shaping the next generation of drug-device innovation. And see how they may be blurring the boundaries between pharmaceutical products, medical devices, software, and diagnostic information.
Safety must be designed into the product and maintained throughout its lifecycle. Join experts as they examine who owns the overall benefit-risk assessment, when critical decisions should be made and what evidence is needed to manage risks over time.
A safety signal does not come with a label saying “drug”, “device” or “system”. A reported adverse event may be caused by the medicinal product, a device malfunction, an interaction between the two, or the way the product is used. Explore how pharmacovigilance, device vigilance and post-market surveillance can be connected to identify the real signal before it gets lost between systems and how the tools and systems we have can work together instead of against each other.
Detecting a signal is only the beginning. Once a potential problem has been identified, who connects the information across manufacturers, suppliers, pharmacovigilance, device surveillance, quality and regulatory functions? Explore how organisational boundaries and fragmented responsibilities can delay investigation, escalation and corrective action — and what mechanisms can prevent this.
What must change to make combination products safer, and what can we do today? Our closing panel will bring together the conference’s key insights and challenge participants to identify practical actions for industry, regulators and other stakeholders.
Explore other relevant upcoming events.

The 7th Trinational HealthTech Days connects biotech, medtech and digital health startups with investors, corporates and healthcare innovation leaders from across Europe. The 2026 program c...

Pharma & Medtech Conference & Exhibition 2026 brings together pharmaceutical and medical technology professionals in Dublin to explore manufacturing, innovation, regulatory compliance and d...

The 10th edition of the Digi-Tech Pharma & AI 2027 Conference is a leading platform uniting pharmaceutical and technology leaders, healthcare innovators, regulatory authorities and solution...

A two-day regulatory affairs conference focused on turning regulatory information into actionable intelligence across pharmaceuticals, medical devices, and IVDs. Sessions address regulatory...